[en] ARMD is the leading cause of visual loss in the 55 and older population. Recent data suggests that low dose external beam irradiation seems to have a beneficial effect in stabilizing the central visual acuity, by arresting or delaying the progression of the central scotoma. The authors decided to use a newly designed Strontium-90 Macular Applicator in a pilot study to ascertain its effectiveness in controlling exudative, age related macular degeneration. Two groups of 10 patients each were treated. The first group received a total dose of 10 Gy at 1.5 mm depth in a total time of 4 minutes and 20 seconds, fractionated in 4 applications of 1 minute and 5 seconds with 1 minute rest in between to allow blood perfusion. The second group was treated with 15 Gy at the same depth of 1.5 mm in a total time of 6 minutes, in 5 fractions of 1 minute and 20 seconds and 1 minute rest. The first group of patients had a mean follow-up time of 6.7 months, the visual acuity improved at least two Snellen gradations in one eye (10%), stabilized in six eyes (60%) and worsened in three eyes (30%). Among the nine eyes with fluorescein angiographic documentation at four and six months post treatment, the choroidal neovascular membrane remained stable in eight eyes (85%). Strontium-90 brachytherapy appears to be an effective treatment for stabilizing the extent of choroidal neovascular membrane growth on a short term basis. Whether this therapy stabilizes or improves visual acuity, as compared to the natural history of the untreated disease, remains uncertain. The second group will complete six months follow-up soon and the results will be discussed at the time of this presentation